Study S002304
A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes Mellitus
Registration
Registered primary outcomes
- Percentage change in body weight from baseline to Week 76 [Baseline and at Week 76]
- Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76 [Baseline and at Week 76]
Linked records (3)
Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
| Record | Title | Year | Design | Identifiers | Link basis |
|---|---|---|---|---|---|
| R0007237 | Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes. Wharton S, The New England journal of medicine | 2026 | Randomized trial | PMID 42820639DOI | cites ClinicalTrials.gov:NCT06066528; registry reference DERIVED:42820639 |
| R0013326 | Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes. Wharton S, Diabetes, obesity & metabolism | 2026 | Randomized trial | PMID 41216778DOI | cites ClinicalTrials.gov:NCT06066528; registry reference DERIVED:41216778 |
| R0015290 | Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2). Wharton S, Obesity (Silver Spring, Md.) | 2025 | Protocol | PMID 39495965DOI | cites ClinicalTrials.gov:NCT06066528 |